Get all premium features to the best stock analysis tool

Vaxart OTCMKTS: VXRT said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027.

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript